

# Martin Posch

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1676891/publications.pdf>

Version: 2024-02-01

156  
papers

6,285  
citations

76196

40  
h-index

79541

73  
g-index

171  
all docs

171  
docs citations

171  
times ranked

6698  
citing authors

#	ARTICLE	IF	CITATIONS
1	Reliability and validity of the Medical Research Council (MRC) scale and a modified scale for testing muscle strength in patients with radial palsy. <i>Journal of Rehabilitation Medicine</i> , 2008, 40, 665-671.	0.8	429
2	A graphical approach to sequentially rejective multiple test procedures. <i>Statistics in Medicine</i> , 2009, 28, 586-604.	0.8	311
3	A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 591-605.	3.0	220
4	Adaptive designs for confirmatory clinical trials. <i>Statistics in Medicine</i> , 2009, 28, 1181-1217.	0.8	208
5	Recursive Combination Tests. <i>Journal of the American Statistical Association</i> , 2002, 97, 236-244.	1.8	203
6	Testing and estimation in flexible group sequential designs with adaptive treatment selection. <i>Statistics in Medicine</i> , 2005, 24, 3697-3714.	0.8	194
7	Morphine Decreases Clopidogrel Concentrations and Effects. <i>Journal of the American College of Cardiology</i> , 2014, 63, 630-635.	1.2	187
8	Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology. <i>Statistics in Medicine</i> , 2009, 28, 1445-1463.	0.8	168
9	Adaptive Two Stage Designs and the Conditional Error Function. <i>Biometrical Journal</i> , 1999, 41, 689-696.	0.6	132
10	Implant survival in mandibles of irradiated oral cancer patients. <i>Clinical Oral Implants Research</i> , 2006, 17, 337-344.	1.9	129
11	Impact of dental implant length on early failure rates: a meta-analysis of observational studies. <i>Journal of Clinical Periodontology</i> , 2011, 38, 856-863.	2.3	128
12	Graphical approaches for multiple comparison procedures using weighted Bonferroni, Simes, or parametric tests. <i>Biometrical Journal</i> , 2011, 53, 894-913.	0.6	123
13	Clinical Features, Classification and Prognosis of Migraine and Tension-Type Headache in Children and Adolescents: A Long-Term Follow-Up Study. <i>Cephalalgia</i> , 2006, 26, 820-830.	1.8	116
14	Issues in designing flexible trials. <i>Statistics in Medicine</i> , 2003, 22, 953-969.	0.8	106
15	The Assessment of Four Different Methods to Verify Tracheal Tube Placement in the Critical Care Setting. <i>Anesthesia and Analgesia</i> , 1999, 88, 766-770.	1.1	105
16	Quality of life in patients with non-metastatic differentiated thyroid cancer under thyroxine supplementation therapy. <i>Supportive Care in Cancer</i> , 2003, 11, 597-603.	1.0	94
17	Methods for identification and confirmation of targeted subgroups in clinical trials: A systematic review. <i>Journal of Biopharmaceutical Statistics</i> , 2016, 26, 99-119.	0.4	93
18	Win "Stay, Lose" Shift Strategies for Repeated Games "Memory Length, Aspiration Levels and Noise. <i>Journal of Theoretical Biology</i> , 1999, 198, 183-195.	0.8	90

#	ARTICLE	IF	CITATIONS
19	Adaptive Dunnett tests for treatment selection. <i>Statistics in Medicine</i> , 2008, 27, 1612-1625.	0.8	89
20	Nanoscale silver possesses broad-spectrum antimicrobial activities and exhibits fewer toxicological side effects than silver sulfadiazine. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2012, 8, 478-488.	1.7	89
21	Muscle Fatigue and Fatigue-Related Biomechanical Changes During a Cyclic Lifting Task. <i>Spine</i> , 2003, 28, 1810-1820.	1.0	86
22	The efficiency of adapting aspiration levels. <i>Proceedings of the Royal Society B: Biological Sciences</i> , 1999, 266, 1427-1435.	1.2	78
23	Attainability of boundary points under reinforcement learning. <i>Games and Economic Behavior</i> , 2005, 53, 110-125.	0.4	78
24	The Evolution of Master Protocol Clinical Trial Designs: A Systematic Literature Review. <i>Clinical Therapeutics</i> , 2020, 42, 1330-1360.	1.1	74
25	Diuretic potential of energy drinks. <i>Amino Acids</i> , 2006, 31, 81-83.	1.2	72
26	Diagnostic accuracy and reliability of muscle strength and endurance measurements in patients with chronic low back pain. <i>Journal of Rehabilitation Medicine</i> , 2009, 41, 613-619.	0.8	71
27	Selection and bias—Two hostile brothers. <i>Statistics in Medicine</i> , 2010, 29, 1-13.	0.8	69
28	Genome-wide CpG island methylation analyses in non-small cell lung cancer patients. <i>Carcinogenesis</i> , 2013, 34, 513-521.	1.3	67
29	Interim Analysis and Sample Size Reassessment. <i>Biometrics</i> , 2000, 56, 1170-1176.	0.8	66
30	Variations in end-of-life practices in intensive care units worldwide (Ethicus-2): a prospective observational study. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1101-1110.	5.2	66
31	Adaptive clinical trial designs for European marketing authorization: a survey of scientific advice letters from the European Medicines Agency. <i>Trials</i> , 2014, 15, 383.	0.7	64
32	The German version of the Oxford shoulder score—cross-cultural adaptation and validation. <i>Archives of Orthopaedic and Trauma Surgery</i> , 2004, 124, 531-536.	1.3	63
33	Current Statistical Considerations and Regulatory Perspectives on the Planning of Confirmatory Basket, Umbrella, and Platform Trials. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 1059-1067.	2.3	61
34	Sharing clinical trial data on patient level: Opportunities and challenges. <i>Biometrical Journal</i> , 2015, 57, 8-26.	0.6	60
35	T cell senescence and contraction of T cell repertoire diversity in patients with chronic obstructive pulmonary disease. <i>Clinical and Experimental Immunology</i> , 2009, 155, 466-475.	1.1	56
36	Physiotherapy-Based Rehabilitation Following Disc Herniation Operation. <i>Spine</i> , 2007, 32, 2041-2049.	1.0	51

#	ARTICLE	IF	CITATIONS
37	Respective potencies of Botox® and Dysport® in a human skin model: A randomized, double-blind study. <i>Movement Disorders</i> , 2009, 24, 231-236.	2.2	48
38	Impact of Pneumococcal Vaccination on Morbidity and Mortality of Geriatric Patients: A Case-Controlled Study. <i>Gerontology</i> , 2003, 49, 246-250.	1.4	46
39	CROSS-CULTURAL ADAPTATION OF THE MINNESOTA LIVING WITH HEART FAILURE QUESTIONNAIRE FOR GERMAN-SPEAKING PATIENTS. <i>Journal of Rehabilitation Medicine</i> , 2001, 33, 182-186.	0.8	44
40	Two-stage designs for experiments with a large number of hypotheses. <i>Bioinformatics</i> , 2005, 21, 3771-3777.	1.8	44
41	Cycling in a stochastic learning algorithm for normal form games. <i>Journal of Evolutionary Economics</i> , 1997, 7, 193-207.	0.8	42
42	Adaptive designs for subpopulation analysis optimizing utility functions. <i>Biometrical Journal</i> , 2015, 57, 76-89.	0.6	42
43	An international comparison of age and sex dependency of COVID-19 deaths in 2020: a descriptive analysis. <i>Scientific Reports</i> , 2021, 11, 19143.	1.6	42
44	Cancer Drug Development and the Evolving Regulatory Framework for Companion Diagnostics in the European Union. <i>Clinical Cancer Research</i> , 2014, 20, 1458-1468.	3.2	40
45	Efficient Adaptive Designs for Clinical Trials of Interventions for COVID-19. <i>Statistics in Biopharmaceutical Research</i> , 2020, 12, 483-497.	0.6	40
46	Evidence supporting regulatory-decision making on orphan medicinal products authorisation in Europe: methodological uncertainties. <i>Orphanet Journal of Rare Diseases</i> , 2018, 13, 206.	1.2	37
47	Sequential Tests for Noninferiority and Superiority. <i>Biometrics</i> , 2003, 59, 106-114.	0.8	35
48	Repeated confidence intervals for adaptive group sequential trials. <i>Statistics in Medicine</i> , 2007, 26, 5422-5433.	0.8	34
49	Type I error rate control in adaptive designs for confirmatory clinical trials with treatment selection at interim. <i>Pharmaceutical Statistics</i> , 2011, 10, 96-104.	0.7	33
50	Gatekeepers and Enablers: How Drug Regulators Respond to a Challenging and Changing Environment by Moving Toward a Proactive Attitude. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 93, 425-432.	2.3	33
51	The use of external controls: To what extent can it currently be recommended?. <i>Pharmaceutical Statistics</i> , 2021, 20, 1002-1016.	0.7	33
52	Exact Confidence Bounds Following Adaptive Group Sequential Tests. <i>Biometrics</i> , 2009, 65, 539-546.	0.8	32
53	Methods for the analysis of multiple endpoints in small populations: A review. <i>Journal of Biopharmaceutical Statistics</i> , 2019, 29, 1-29.	0.4	32
54	Sample Size Reassessment and Hypothesis Testing in Adaptive Survival Trials. <i>PLoS ONE</i> , 2016, 11, e0146465.	1.1	32

#	ARTICLE	IF	CITATIONS
55	Load-dependence of fatigue related changes in tremor around 10 Hz. <i>Clinical Neurophysiology</i> , 2000, 111, 106-111.	0.7	31
56	Does the low prevalence affect the sample size of interventional clinical trials of rare diseases? An analysis of data from the aggregate analysis of clinicaltrials.gov. <i>Orphanet Journal of Rare Diseases</i> , 2017, 12, 44.	1.2	31
57	Reliability of EMG time-frequency measures of fatigue during repetitive lifting. <i>Medicine and Science in Sports and Exercise</i> , 2002, 34, 1316-1323.	0.2	30
58	Conditional Rejection Probabilities of Student's t-test and Design Adaptations. <i>Biometrical Journal</i> , 2004, 46, 389-403.	0.6	30
59	Prospective, Randomized, Multicenter, Double-Blind Placebo-Controlled Trial Comparing Adjuvant Interferon Alfa and Isotretinoin With Interferon Alfa Alone in Stage IIA and IIB Melanoma: European Cooperative Adjuvant Melanoma Treatment Study Group. <i>Journal of Clinical Oncology</i> , 2005, 23, 8655-8663.	0.8	30
60	Recent advances in methodology for clinical trials in small populations: the InSPiRe project. <i>Orphanet Journal of Rare Diseases</i> , 2018, 13, 186.	1.2	30
61	Rehabilitation of the severely atrophied maxilla by horseshoe Le Fort I osteotomy (HLFO). <i>Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics</i> , 2004, 97, 683-692.	1.6	29
62	Optimized adaptive enrichment designs. <i>Statistical Methods in Medical Research</i> , 2019, 28, 2096-2111.	0.7	28
63	Optimized multi-stage designs controlling the false discovery or the family-wise error rate. <i>Statistics in Medicine</i> , 2008, 27, 4145-4160.	0.8	27
64	Long-term efficacy and respective potencies of botulinum toxin A and B: a randomized, double-blind study. <i>British Journal of Dermatology</i> , 2011, 164, 176-181.	1.4	27
65	Determination of the optimal sample size for a clinical trial accounting for the population size. <i>Biometrical Journal</i> , 2017, 59, 609-625.	0.6	27
66	Elevated levels of interleukin-1 $\gamma$ -converting enzyme and caspase-cleaved cytokeratin-18 in acute myocardial infarction. <i>European Journal of Clinical Investigation</i> , 2007, 37, 372-380.	1.7	26
67	Adaptive designs in clinical trials: from scientific advice to marketing authorisation to the European Medicine Agency. <i>Trials</i> , 2018, 19, 642.	0.7	26
68	Subgroup identification in clinical trials via the predicted individual treatment effect. <i>PLoS ONE</i> , 2018, 13, e0205971.	1.1	26
69	Long-term implant survival in the grafted maxilla: results of a 12-year retrospective study. <i>Clinical Oral Implants Research</i> , 2004, 15, 693-699.	1.9	24
70	Evidence, eminence and extrapolation. <i>Statistics in Medicine</i> , 2016, 35, 2117-2132.	0.8	24
71	Marketing authorisation of orphan medicines in Europe from 2000 to 2013. <i>Drug Discovery Today</i> , 2018, 23, 424-433.	3.2	24
72	Optimizing Trial Designs for Targeted Therapies. <i>PLoS ONE</i> , 2016, 11, e0163726.	1.1	24

#	ARTICLE	IF	CITATIONS
73	Effect of intensive care after cardiac arrest on patient outcome: a database analysis. <i>Critical Care</i> , 2014, 18, R84.	2.5	23
74	Collaborative Platform Trials to Fight COVID-19: Methodological and Regulatory Considerations for a Better Societal Outcome. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 311-320.	2.3	23
75	Multiple Testing for Identifying Effective and Safe Treatments. <i>Biometrical Journal</i> , 2001, 43, 605-616.	0.6	22
76	Early postpartum hysterectomy: incidence and risk factors. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2010, 89, 1040-1044.	1.3	21
77	On the ropivacaine-reducing effect of low-dose sufentanil in intrathecal labor analgesia. <i>Acta Anaesthesiologica Scandinavica</i> , 2010, 54, 1000-1006.	0.7	21
78	On the efficiency of adaptive designs for flexible interim decisions in clinical trials. <i>Journal of Statistical Planning and Inference</i> , 2006, 136, 1956-1961.	0.4	20
79	Decision-theoretic designs for small trials and pilot studies: A review. <i>Statistical Methods in Medical Research</i> , 2016, 25, 1022-1038.	0.7	20
80	Weekends affect mortality risk and chance of discharge in critically ill patients: a retrospective study in the Austrian registry for intensive care. <i>Critical Care</i> , 2017, 21, 223.	2.5	18
81	Design and estimation in clinical trials with subpopulation selection. <i>Statistics in Medicine</i> , 2018, 37, 4335-4352.	0.8	18
82	Effects of N-acetylcysteine against systemic and renal hemodynamic effects of endotoxin in healthy humans. <i>Critical Care Medicine</i> , 2007, 35, 1869-1875.	0.4	18
83	Skateboarding Injuries in Vienna: Location, Frequency, and Severity. <i>PM and R</i> , 2010, 2, 619-624.	0.9	17
84	Wideband UHF ISM-band transceiver supporting multichannel reception and DSSS modulation. , 2013, , .		17
85	Multi-arm group sequential designs with a simultaneous stopping rule. <i>Statistics in Medicine</i> , 2016, 35, 5536-5550.	0.8	17
86	Factors That Influence the Duration of Splint Wear in Peripheral Nerve Lesions. <i>American Journal of Physical Medicine and Rehabilitation</i> , 2003, 82, 86-95.	0.7	16
87	Connections between permutation and $t$ -tests: relevance to adaptive methods. <i>Statistics in Medicine</i> , 2014, 33, 4734-4742.	0.8	16
88	Approaches to sample size calculation for clinical trials in rare diseases. <i>Pharmaceutical Statistics</i> , 2018, 17, 214-230.	0.7	16
89	Analysis of Austrian COVID-19 deaths by age and sex. <i>Wiener Klinische Wochenschrift</i> , 2020, 132, 685-689.	1.0	16
90	Optimal choice of the number of treatments to be included in a clinical trial. <i>Statistics in Medicine</i> , 2009, 28, 1321-1338.	0.8	15

#	ARTICLE	IF	CITATIONS
91	Adaptive graph-based multiple testing procedures. <i>Pharmaceutical Statistics</i> , 2014, 13, 345-356.	0.7	15
92	Use of Nonconcurrent Common Control in Master Protocols in Oncology Trials: Report of an American Statistical Association Biopharmaceutical Section Open Forum Discussion. <i>Statistics in Biopharmaceutical Research</i> , 2022, 14, 353-357.	0.6	15
93	Unplanned adaptations before breaking the blind. <i>Statistics in Medicine</i> , 2012, 31, 4146-4153.	0.8	14
94	Robustness of testing procedures for confirmatory subpopulation analyses based on a continuous biomarker. <i>Statistical Methods in Medical Research</i> , 2019, 28, 1879-1892.	0.7	14
95	Delayed treatment effects, treatment switching and heterogeneous patient populations: How to design and analyze RCTs in oncology. <i>Pharmaceutical Statistics</i> , 2021, 20, 129-145.	0.7	14
96	Fallback tests for co-primary endpoints. <i>Statistics in Medicine</i> , 2016, 35, 2669-2686.	0.8	13
97	Evaluation and calibration of SAPS 3 in patients with COVID-19 admitted to intensive care units. <i>Intensive Care Medicine</i> , 2021, 47, 910-912.	3.9	13
98	HSP-72 Expression in Pre-Transplant Donor Kidney Biopsies and Post-Transplant Outcome. <i>Transplantation</i> , 2004, 78, 292-295.	0.5	12
99	Bridging the gap: a review of dose investigations in paediatric investigation plans. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 898-907.	1.1	12
100	Optimal exact tests for multiple binary endpoints. <i>Computational Statistics and Data Analysis</i> , 2018, 122, 1-17.	0.7	12
101	Applicability and added value of novel methods to improve drug development in rare diseases. <i>Orphanet Journal of Rare Diseases</i> , 2018, 13, 200.	1.2	12
102	Value of information methods to design a clinical trial in a small population to optimise a health economic utility function. <i>BMC Medical Research Methodology</i> , 2018, 18, 20.	1.4	12
103	A critical review of graphics for subgroup analyses in clinical trials. <i>Pharmaceutical Statistics</i> , 2020, 19, 541-560.	0.7	12
104	Hunting for Significance With the False Discovery Rate. <i>Journal of the American Statistical Association</i> , 2009, 104, 832-840.	1.8	11
105	Optimizing subgroup selection in two-stage adaptive enrichment and umbrella designs. <i>Statistics in Medicine</i> , 2021, 40, 2939-2956.	0.8	11
106	Factors associated with physician decision making on withholding cardiopulmonary resuscitation in prehospital medicine. <i>Scientific Reports</i> , 2021, 11, 5120.	1.6	10
107	Sex Differences in Kidney Transplantation: Austria and the United States, 1978-2018. <i>Frontiers in Medicine</i> , 2021, 8, 800933.	1.2	10
108	Estimands and Complex Innovative Designs. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 1183-1190.	2.3	10

#	ARTICLE	IF	CITATIONS
109	Post hoc power estimation in large-scale multiple testing problems. <i>Bioinformatics</i> , 2010, 26, 1050-1056.	1.8	9
110	Cross-platform comparison of microarray data using order restricted inference. <i>Bioinformatics</i> , 2011, 27, 953-960.	1.8	9
111	Perspective on adaptive designs: 4 years European Medicines Agency reflection paper, 1 year draft US FDA guidance "where are we now?". <i>Clinical Investigation</i> , 2012, 2, 235-240.	0.0	9
112	False discovery rate control in two-stage designs. <i>BMC Bioinformatics</i> , 2012, 13, 81.	1.2	9
113	Systematic reviews in paediatric multiple sclerosis and Creutzfeldt-Jakob disease exemplify shortcomings in methods used to evaluate therapies in rare conditions. <i>Orphanet Journal of Rare Diseases</i> , 2016, 11, 16.	1.2	9
114	Platform trials and the future of evaluating therapeutic behavioural interventions. , 2022, 1, 7-8.		9
115	Estimation after blinded sample size reassessment. <i>Statistical Methods in Medical Research</i> , 2018, 27, 1830-1846.	0.7	8
116	Flexible alpha allocation strategies for confirmatory adaptive enrichment clinical trials with a prespecified subgroup. <i>Statistics in Medicine</i> , 2018, 37, 3387-3402.	0.8	8
117	Simultaneous inference for multiple marginal generalized estimating equation models. <i>Statistical Methods in Medical Research</i> , 2020, 29, 1746-1762.	0.7	8
118	A Uniform Improvement of Bonferroni-Type Tests by Sequential Tests. <i>Journal of the American Statistical Association</i> , 2008, 103, 299-308.	1.8	7
119	Nested combination tests with a time-to-event endpoint using a short-term endpoint for design adaptations. <i>Pharmaceutical Statistics</i> , 2019, 18, 329-350.	0.7	7
120	Type I Error Considerations in Master Protocols With Common Control in Oncology Trials: Report of an American Statistical Association Biopharmaceutical Section Open Forum Discussion. <i>Statistics in Biopharmaceutical Research</i> , 2022, 14, 349-352.	0.6	7
121	Short segment stimulation of the anterior transposed ulnar nerve at the elbow. <i>Archives of Physical Medicine and Rehabilitation</i> , 2001, 82, 1171-1175.	0.5	6
122	Maximum type I error rate inflation from sample size reassessment when investigators are blind to treatment labels. <i>Statistics in Medicine</i> , 2016, 35, 1972-1984.	0.8	6
123	Time of Day and its Association with Risk of Death and Chance of Discharge in Critically Ill Patients: A Retrospective Study. <i>Scientific Reports</i> , 2019, 9, 12533.	1.6	6
124	Analysis of the specificity of a COVID-19 antigen test in the Slovak mass testing program. <i>PLoS ONE</i> , 2021, 16, e0255267.	1.1	6
125	Validation of bedside ultrasound to predict lumbar muscle area in the computed tomography in 200 non-critically ill patients: The USVALID prospective study. <i>Clinical Nutrition</i> , 2022, 41, 829-837.	2.3	6
126	A Note on repeated p-values for group sequential designs. <i>Biometrika</i> , 2008, 95, 253-256.	1.3	5



#	ARTICLE	IF	CITATIONS
127	Statistical Challenges in the Conduct and Management of Ongoing Clinical Trials During the COVID-19 Pandemic. <i>Statistics in Biopharmaceutical Research</i> , 2020, 12, 397-398.	0.6	5
128	Robust group sequential designs for trials with survival endpoints and delayed response. <i>Biometrical Journal</i> , 2022, 64, 343-360.	0.6	5
129	Familywise Error Control in Multi-Armed Response-Adaptive Two-Stage Designs. <i>Journal of Biopharmaceutical Statistics</i> , 2011, 21, 818-830.	0.4	4
130	Adaptive Budgets in Clinical Trials. <i>Statistics in Biopharmaceutical Research</i> , 2013, 5, 282-292.	0.6	4
131	Detection of epistatic effects with logic regression and a classical linear regression model. <i>Statistical Applications in Genetics and Molecular Biology</i> , 2014, 13, 83-104.	0.2	4
132	Optimized multiple testing procedures for nested sub-populations based on a continuous biomarker. <i>Statistical Methods in Medical Research</i> , 2020, 29, 2945-2957.	0.7	4
133	Percutaneous ethanol instillation therapy for hepatocellular carcinoma – a randomized controlled trial. <i>Wiener Klinische Wochenschrift</i> , 2008, 120, 608-618.	1.0	3
134	MCP2007 – 5th International Conference on Multiple Comparison Procedures. <i>Biometrical Journal</i> , 2008, 50, 633-635.	0.6	3
135	Sample size reassessment for a two-stage design controlling the false discovery rate. <i>Statistical Applications in Genetics and Molecular Biology</i> , 2015, 14, 429-42.	0.2	3
136	How reliably can ultrasound help determine muscle and adipose tissue thickness in clinical settings? An assessment of intra- and inter-examiner reliability in the USVALID study. <i>European Journal of Clinical Nutrition</i> , 2022, 76, 401-409.	1.3	3
137	Growth prediction model for abdominal aortic aneurysms. <i>British Journal of Surgery</i> , 2022, 109, 211-219.	0.1	3
138	Testing and Interpreting the “Right-Hypothesis” Comment on “Non-proportional Hazards” An Evaluation of the MaxCombo Test in Cancer Clinical Trials – <i>Statistics in Biopharmaceutical Research</i> , 2023, 15, 310-311.	0.6	3
139	The scientific work of Peter Bauer. <i>Biometrical Journal</i> , 2007, 49, 651-653.	0.6	2
140	Efficient two-stage sequential arrays of proof of concept studies for pharmaceutical portfolios. <i>Statistical Methods in Medical Research</i> , 2021, 30, 396-410.	0.7	2
141	Are p-values Useful to Judge the Evidence Against the Null Hypotheses in Complex Clinical Trials? A Comment on “The Role of p-values in Judging the Strength of Evidence and Realistic Replication Expectations” – <i>Statistics in Biopharmaceutical Research</i> , 2021, 13, 43-45.	0.6	2
142	Assessment of tumour-agnostic therapies in basket trials. <i>Lancet Oncology</i> , The, 2022, 23, e8.	5.1	2
143	Statistical advising: Professional development opportunities for the biostatistician. <i>Statistics in Medicine</i> , 2022, 41, 847-859.	0.8	2
144	MCP2009 – 6 <sup>th</sup> International Conference on Multiple Comparison Procedures. <i>Biometrical Journal</i> , 2010, 52, 705-707.	0.6	1

#	ARTICLE	IF	CITATIONS
145	MCP2011â€”The 7th international conference on multiple comparison procedures. Biometrical Journal, 2013, 55, 271-274.	0.6	1
146	Response to comments on Jaki et al., A proposal for a new PhD level curriculum on quantitative methods for drug development. Pharm Stat17(5):593â€”606, Sep/Oct 2018., DOI: <a href="https://doi.org/10.1002/pst.1873">https://doi.org/10.1002/pst.1873</a> . Pharmaceutical Statistics, 2019, 18, 284-286.	0.7	1
147	A multiple comparison procedure for doseâ€”finding trials with subpopulations. Biometrical Journal, 2020, 62, 53-68.	0.6	1
148	Testing Procedures for Claiming Success on at Least k Out of m Hypotheses with an Application to Biosimilar Development. Statistics in Biopharmaceutical Research, 2021, 13, 106-112.	0.6	1
149	Association of Acute Kidney Injury Receiving Kidney Replacement Therapy With Prognosis of Critically Ill Patients With and Without Cancer: A Retrospective Study. Critical Care Medicine, 2021, 49, 1932-1942.	0.4	1
150	Statistical Issues and Challenges in Clinical Trials for COVID-19 Treatments, Vaccines, Medical Devices and Diagnostics. Statistics in Biopharmaceutical Research, 0, , 1-4.	0.6	1
151	Special Issue for Dealing with Multiplicity in Drug Development: Current State and New Directions â€” Guest Editors' Note. Journal of Biopharmaceutical Statistics, 2011, 21, 581-582.	0.4	0
152	Author's reply. Biometrical Journal, 2013, 55, 266-266.	0.6	0
153	Quantitative approaches underpinning decision making. Biometrical Journal, 2019, 61, 1103-1103.	0.6	0
154	SAT0104â€”...INITIAL EVIDENCE FOR THE NEED OF A DUAL TREAT-TO-TARGET STRATEGY IN PATIENTS WITH RHEUMATOID ARTHRITIS. , 2019, , .		0
155	The impact of the SARSâ€”CoV â€”2 pandemic on the ongoing prospective, international, multicentre observational study assessing the preoperative anaemia prevalence in surgical patients (ALICEâ€”trial). Transfusion Medicine, 2021, 31, 387-390.	0.5	0
156	Rationale for the update algorithm of the graphical approach to sequentially rejective multiple test procedures. Pharmaceutical Statistics, 2022, 21, 757-763.	0.7	0